文献速递心境障碍焦虑、强迫与应激相关障碍会诊联络精神医学

妊娠期精神药物安全性:一项伞状综述

Safety of psychotropic medications in pregnancy: an umbrella review.
PubMed 文献 · Mol Psychiatry · 2024-09-12

该伞状综述系统评估了妊娠期精神药物使用与孕产妇及胎儿不良健康结局关联的证据强度,纳入21项观察性研究的Meta分析,涵盖17,290,755名参与者。未发现令人信服或高度提示级别的证据;早产、小于胎龄儿、先天畸形等关联仅为提示性证据。

要点

  • 未发现妊娠期精神药物与不良结局间令人信服或高度提示级别的证据。
  • 任何精神障碍或抑郁症孕妇任一孕期使用抗抑郁药与早产呈提示性关联。
  • 抑郁症孕妇任一孕期使用SSRI与小于胎龄儿呈提示性关联。

核心结论

  • 该伞状综述未发现妊娠期精神药物使用与不良健康结局之间存在令人信服或高度提示级别的证据。

研究设计与样本

  • 纳入21项观察性研究的系统综述与Meta分析,涵盖17,290,755名参与者。
  • 采用AMSTAR 2评估Meta分析质量(高质量1项、低质量12项、极低质量8项),采用NOS评估单项研究质量。
  • 证据可信度分级为令人信服、高度提示、提示、弱或无统计学显著性。

主要发现

  • 任何精神障碍孕妇任一孕期使用抗抑郁药与早产呈提示性关联,等效比值比为1.62(95%CI 1.24-2.12)。
  • 抑郁症孕妇任一孕期使用抗抑郁药与早产呈提示性关联,等效比值比为1.65(95%CI 1.34-2.02)。
  • 抑郁症孕妇任一孕期使用SSRI与小于胎龄儿呈提示性关联,等效比值比为1.50(95%CI 1.19-1.90)。
  • 抑郁症或焦虑症孕妇妊娠早期使用帕罗西汀与婴儿重大先天畸形呈提示性关联,等效比值比为1.24(95%CI 1.09-1.40)。
  • 抑郁症或焦虑症孕妇妊娠早期使用帕罗西汀与婴儿心脏畸形呈提示性关联,等效比值比为1.28(95%CI 1.11-1.47)。

关键数值与推荐

  • 证据可信度分级标准包括令人信服、高度提示、提示、弱或无统计学显著性。
  • 质量评估工具为AMSTAR 2和纽卡斯尔-渥太华量表(NOS)。

局限性

  • Meta分析质量评估显示高质量仅1项,低质量12项,极低质量8项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Weighing risks and benefits of the use of psychotropic medications during pregnancy remains a challenge worldwide. We systematically assessed the strength of associations between psychotropic medication use in pregnant people with mental disorders and various adverse health outcomes in both pregnant people and foetuses. Systematic reviews with meta-analyses of observational studies investigating the association between exposure to psychotropic medication in pregnancy and any adverse health outcomes were included. Credibility was graded into convincing, highly suggestive, suggestive, weak or not significant. Quality of the meta-analyses and of individual studies were assessed with A Measurement Tool to Assess Systematic Reviews 2 (AMSTAR 2) the Newcastle-Ottawa Scale (NOS), respectively. We considered 21 meta-analyses encompassing 17,290,755 participants (AMSTAR 2 high = 1, low = 12, or critically low = 8). Evidence was suggestive for: (1) preterm birth in pregnant people with either any mental disorder (equivalent odds ratio 1.62 (95% confidence interval 1.24-2.12) or depression (1.65 [1.34-2.02]) receiving antidepressants during any trimester of pregnancy; (2) small for gestational age for pregnant people with depression receiving a SSRI during any trimester of pregnancy (1.50 [1.19-1.90]); and (3) major congenital malformation (1.24 [1.09-1.40]) or cardiac malformations (1.28 [1.11-1.47]) in babies for pregnant people with depression or anxiety receiving paroxetine during first trimester of pregnancy. Additional associations were supported by weak evidence, or were not statistically significant. This umbrella review found no convincing or highly suggestive level of evidence of adverse health outcomes associated with psychotropic medication use in pregnant people with mental disorders.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Fabiano N, Wong S, Gupta A, et al. Safety of psychotropic medications in pregnancy: an umbrella review. Mol Psychiatry. 2024. PMID: 39266712. doi:10.1038/s41380-024-02697-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。